Epigenetic state determines the in vivo efficacy of STING agonist therapy

Rana Falahat; Anders Berglund; Patricio Perez-Villarroel; Ryan M. Putney; Imene Hamaidi; Sungjune Kim; Shari Pilon-Thomas; Glen N. Barber; James J. Mulé

doi:10.1038/s41467-023-37217-1

Nature Communications (Mar 2023)

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Rana Falahat,
Anders Berglund,
Patricio Perez-Villarroel,
Ryan M. Putney,
Imene Hamaidi,
Sungjune Kim,
Shari Pilon-Thomas,
Glen N. Barber,
James J. Mulé

Affiliations

Rana Falahat: Department of Immunology, Moffitt Cancer Center
Anders Berglund: Department of Biostatistics and Bioinformatics, Moffitt Cancer Center
Patricio Perez-Villarroel: Department of Immunology, Moffitt Cancer Center
Ryan M. Putney: Department of Biostatistics and Bioinformatics, Moffitt Cancer Center
Imene Hamaidi: Department of Immunology, Moffitt Cancer Center
Sungjune Kim: Department of Immunology, Moffitt Cancer Center
Shari Pilon-Thomas: Department of Immunology, Moffitt Cancer Center
Glen N. Barber: Department of Cell Biology, University of Miami Miller School of Medicine
James J. Mulé: Department of Immunology, Moffitt Cancer Center

DOI: https://doi.org/10.1038/s41467-023-37217-1
Journal volume & issue: Vol. 14, no. 1
pp. 1 – 16

Abstract

Read online

STING agonists have shown limited efficacy in early-phase clinical trials despite promising pre-clinical data. This study shows the potential clinical relevance of the use of combination STING agonists and demethylating agent therapies to induce the expression of STING.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal